Can platelet count be controlled with ticagrelor in patients with essential thrombocythaemia? A case series.

ABSTRACT:

Background

Essential thrombocythaemia (ET) is defined as a myeloproliferative neoplasm with a tendency to haemorrhage and thrombosis. Acute coronary thrombosis can be observed in 1 out of 10 patients. The management of ET patients with acute coronary syndrome (ACS) is a complex clinical condition that requires close follow-up.

Case summary

Case-1: a 52-year-old female patient with a diagnosis of ET with Janus kinase (JAK)--2 mutation, despite using cytoreductive agents, platelet counts could not be controlled. Platelet counts started to follow a normal course with the ticagrelor treatment given after ACS. Case-2: a 49-year-old female patient who was given ticagrelor treatment after ACS was found to have JAK-2+ ET. The patient whose platelet count returned to no

SUBMITTER: Yılmaz S 

PROVIDER: S-EPMC9933940 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature